Table 3.

Changes in secondary outcomes from baseline to week 12

	MDI group	LIX group	P
HbA1c (%)	−0.05 ± 0.37	+0.04 ± 0.38	0.36
M‐value	+2.3 ± 32.2	−6.8 ± 49.7	0.59
Body weight (kg)	+0.6 ± 1.8	−2.5 ± 1.8	<0.01

Values are expressed as mean ± standard deviation. Changes in parameters described as mean ± standard deviation between 0 and 12 weeks were analyzed using a Mann–Whitney U‐test. HbA1c, glycated hemoglobin; LIX group, the group that switched from multiple daily insulin injection therapy to combination therapy with lixisenatide and basal insulin; MDI group, the group that continued multiple daily insulin injection therapy.